Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer.

[8] In November 2023, capivasertib was approved in the United States for people with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer when used in combination with fulvestrant.

[8][9][10] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

[11] Capivasertib, used in combination with fulvestrant (Faslodex), is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.

[8] The FDA granted the application for capivasertib fast track designation.